Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Aug 13, 2021. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q2 2021. Go to the latest filing (Q3 2026)

12.3B USDQ2 2021
Total value of stock positions
12.3B USD
Positions
58
Share of the ten largest
68.2%

The ten largest positions Q2 2021

  1. Liberty Global PLC 11.9%▼ −1.1%
  2. Intel 9.9%▼ −6.7%
  3. eBay Inc. 8.5%▼ −18.7%
  4. Qorvo Inc 8.5%▲ +2.1%
  5. Viasat Inc 6.6%unchanged
  6. Alphabet Inc. (Class C) 5.9%unchanged
  7. Micron Technology 5.0%▲ +32.1%
  8. Meta Platforms 4.4%▲ +19.3%
  9. Translate Bio Inc 4.0%unchanged
  10. Willis Towers Watson 3.5%▼ −24.3%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q2 2021

Positions Q2 2021 per 13F filing, 4 of 4
Symbol Weight Shares Reported value Change Held since
Theravance Biopharma Inc 1.2% 9,910,168 143.9M USD +13.5% increased Q2 2014 29 quarters
Qorvo Inc 8.5% 5,334,466 1.0B USD +2.1% increased Q1 2017 18 quarters
META Meta Platforms 4.4% 1,547,000 537.9M USD +19.3% increased Q1 2020 6 quarters
MU Micron Technology 5.0% 7,163,416 608.7M USD +32.1% increased Q3 2020 4 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 1 position in convertible bonds and bonds worth 28.6M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Biopharma Inc principal 30.0M USD 28.6M USD

Breakdown by sector

  • Technology 14.9%
  • Communication Services 10.3%
  • Consumer Discretionary 8.5%
  • Financials 3.5%
  • Materials 2.6%
  • Utilities 2.5%
  • not in our coverage 57.7%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close